Akari Therapeutics Plc
(NASDAQ : AKTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-0.10%41.950.9%$966.66m
MRKMerck & Co., Inc.
-0.19%80.820.6%$795.94m
JNJJohnson & Johnson
-0.21%138.470.7%$771.19m
BMYBristol-Myers Squibb Company
-0.95%47.291.4%$652.82m
LLYEli Lilly and Company
-0.59%117.291.0%$497.39m
ABBVAbbVie, Inc.
-1.28%80.552.2%$443.36m
NVSNovartis AG Sponsored ADR
0.41%84.250.2%$190.72m
AZNAstraZeneca PLC Sponsored ADR
0.25%38.711.3%$190.50m
GSKGlaxoSmithKline plc Sponsored ADR
-0.67%39.930.2%$102.00m
NVONovo Nordisk A/S Sponsored ADR Class B
-1.14%47.850.1%$63.38m
SNYSanofi Sponsored ADR
-0.76%41.770.2%$48.14m
LCILannett Company, Inc.
-2.15%5.9236.7%$9.79m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.57%2.351.6%$3.31m
EPIXESSA Pharma Inc
-6.51%2.010.1%$0.01m

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.